List of works - Daniela Žáčková

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

scientific article published on 29 May 2020

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

scientific article published on June 2012

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

scientific article

BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing.

scientific article

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.

scientific article

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

scientific article published on 23 July 2013

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

scientific article published on 06 October 2020

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

scientific article

Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex

scientific article published on 09 December 2019

Evaluation of two CE-IVD tests for <i>BCR-ABL1</i> transcript monitoring of chronic myeloid leukemia patients

scientific article published on 25 December 2020

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction.

scientific article published in March 2010

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

scientific article

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

scientific article published in July 2022

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

scientific article

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

scientific article published on 28 May 2013

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

scientific article

Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia

scientific article published on 09 February 2020

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

scientific article published in May 2010

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

scientific article published on 14 September 2019

Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia.

scientific article

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

scientific article published on 29 April 2016

Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.

scientific article

Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide

scientific article published on 01 June 2009

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

article published in 2013

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

scientific article published on 29 June 2020

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

scientific article published in February 2024

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

scientific article published on July 2010

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

scientific article published on 08 September 2011

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

List of works by Daniela Žáčková

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.

BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing.

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex

Evaluation of two CE-IVD tests for <i>BCR-ABL1</i> transcript monitoring of chronic myeloid leukemia patients

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction.

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia.

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.

Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide

The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients